🇺🇸 decitabine injection in United States

27 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Bone Marrow Failure — 7 reports (25.93%)
  2. Lung Infection — 3 reports (11.11%)
  3. Neutropenia — 3 reports (11.11%)
  4. Bacteraemia — 2 reports (7.41%)
  5. Blood Culture Positive — 2 reports (7.41%)
  6. Hepatic Function Abnormal — 2 reports (7.41%)
  7. Nausea — 2 reports (7.41%)
  8. Pneumonia — 2 reports (7.41%)
  9. Vomiting — 2 reports (7.41%)
  10. White Blood Cell Count Decreased — 2 reports (7.41%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is decitabine injection approved in United States?

decitabine injection does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for decitabine injection in United States?

Janssen Korea, Ltd., Korea is the originator. The local marketing authorisation holder may differ — check the official source linked above.